Atopic comorbidities associated with granuloma annulare: A case-control study of the All of Us database

Joshi, Tejas P; Chen, Victoria; Dong, Jen-Li; Golden, Katelyn; Iacobucci, Alexander; Lim, Yuli; Morrow, Beatrice; Duvic, Madeleine

doi:10.1016/j.jaad.2023.02.012

Cited by 7 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study reported by Min et al showed a 5400-fold increase in interleukin-4 (IL-4) in GA lesions compared to normal skin which inspired an investigation into the association of GA with atopic comorbidities [ 3 ]. Interestingly, patients with GA were significantly more likely to have experience with allergic rhinitis, asthma, and eczema [ 12 ]. Therefore, it could be suggested that the mechanistic culprit responsible for GA is Th2 dysregulation.…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Refractory Generalized Granuloma Annulare with Upadacitinib

Coican,

Meckley,

Sagasser

et al. 2024

Case Reports in Dermatological Medicine

View full text Add to dashboard Cite

Granuloma annulare is a poorly understood dermatosis that, when generalized, can occur in up to 15 percent of patients. In these cases, treatment is frustrating and experimental. We report a case of a 60‐year‐old woman and a 41‐year‐old woman who demonstrated resolution of recalcitrant, generalized granuloma annulare (GA) following oral treatment with upadacitinib. After showing little to no response to other various treatments, such as steroids, antibiotic regimens, and systemic therapies, each patient was started on 15 mg of daily upadacitinib. At 2 months, one patient had complete clearance of all lesions while the other patient experienced noticeable improvement. Within 4 months, the other patient reached total resolution of her lesions. These cases provide evidence of a therapeutic option that may shorten disease duration and provide relief from cutaneous disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Refractory Generalized Granuloma Annulare with Upadacitinib

Coican,

Meckley,

Sagasser

et al. 2024

Case Reports in Dermatological Medicine

View full text Add to dashboard Cite

show abstract

“…However, recent research suggests that T-helper 2 cell dysregulation may also be a component of GA pathogenesis. 7 , 8 It is possible that a differing balance of the 2 competing cytokine pathways among different patients results in a heterogenous response to treatment.…”

mentioning

confidence: 99%

Apremilast for the treatment of generalized granuloma annulare: A case series of 8 patients

Joshi¹,

Tschen²

2023

JAAD Case Reports

Self Cite

View full text Add to dashboard Cite

Bibliographie « Printemps 2024 »

Cribier

2024

Annales de Dermatologie et de Vénéréologie - FMC

View full text Add to dashboard Cite

Atopic comorbidities associated with granuloma annulare: A case-control study of the All of Us database

Cited by 7 publications

References 4 publications

Successful Treatment of Refractory Generalized Granuloma Annulare with Upadacitinib

Successful Treatment of Refractory Generalized Granuloma Annulare with Upadacitinib

Apremilast for the treatment of generalized granuloma annulare: A case series of 8 patients

Bibliographie « Printemps 2024 »

Contact Info

Product

Resources

About